Cyclerion Therapeutics Inc (CYCN) Stock Price, Quote & News

Company Profile

Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to treat cardiovascular diseases; and Praliciguat, a systemic sGC stimulator for the treatment of rare kidney disease. It has a license agreement with Akebi...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 327 8778

Website: www.cyclerion.com

Address:

245 First Street, Riverview II, 18th Floor, Cambridge, United States

skyrockets_Inc Dec. 5 at 3:01 PM

$CYCN Short interest on 11/14 was 335,301 shares. Last time it was anywhere near this high was this time last year when it was ~700k shares...and a week or two later is when it popped from 1.50 to $9+ . Is history ready to repeat? High short interest = squeeze time

1 · Reply

Mahdinur Dec. 4 at 6:43 PM

$CYCN $SMX $AGH $SMX $AGH $GRI

1 · Reply

Eliza1 Dec. 4 at 6:43 PM

$CYCN buy $SMX or $AGH- a better chance for gains. Be careful with $SMX. $AGH has lots of gaps over $7.5

0 · Reply

StockTwitsGhost Dec. 4 at 5:23 PM

$CYCN Thank you for selling, now we can retrace $9+

2 · Reply

skyrockets_Inc Dec. 4 at 5:07 PM

$CYCN the retrace to the 50day SMA is happening as predicted. Will re-trace back to ~$2 range soon IMO.

0 · Reply

AshleySchaeffer_BMW Dec. 4 at 4:38 PM

$CYCN vol perking up....

0 · Reply

dbr_island Dec. 4 at 4:34 PM

🚨EPOW🚨 loading here and can’t wait to show you my buys later once it runs BIG…… Just like QCLS 👇💰💰💰💰 $CYCN watching

0 · Reply

Eliza1 Dec. 3 at 11:35 PM

$CYCN time to sell

1 · Reply

Eliza1 Dec. 3 at 10:04 PM

$CAPR incredible move. This company has been around years with many RS but, still hangs in there. $$CYCN And $AGH could be next-

0 · Reply

Eliza1 Dec. 3 at 3:00 PM

$CYCN look at $CAPR for what a positive PR can do when you actually have good news! An 8k is required but not enough.

1 · Reply

Cyclerion Therapeutics, Inc. - Pre Recorded Special Call

Sep 23, 2025, 4:01 PM EDT - 2 months ago

Cyclerion Announces Transformational Relaunch as a Neuropsychiatric Company

Dec 17, 2024, 8:08 AM EST - 1 year ago

Cyclerion's sGC Stimulator Portfolio Generates Revenues to Enable Company Growth

Aug 7, 2024, 7:00 AM EDT - 1 year ago

Regina Graul, Ph.D., Promoted to Chief Executive Officer

Dec 4, 2023, 8:00 AM EST - 2 years ago

Cyclerion Appoints Regina Graul, Ph.D., as President

Nov 30, 2023, 6:16 PM EST - 2 years ago

Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator

Jul 31, 2023, 7:00 AM EDT - 2 years ago

Tisento Launches with $81 Million From Top-Tier Investor Syndicate and Promising Cyclerion Assets

Jun 1, 2023, 4:00 PM EDT - 2 years ago

Cyclerion Regains Compliance with Nasdaq Minimum Bid Price Requirement

May 15, 2023, 1:00 PM EDT - 2 years ago

Cyclerion Announces Reverse Stock Split

May 11, 2023, 6:00 PM EDT - 2 years ago

Cyclerion Announces Definitive Agreement for Zagociguat and CY3018

May 11, 2023, 6:00 PM EDT - 2 years ago

Cyclerion Announces Corporate Updates and Q1 2023 Financial Results

Apr 3, 2023, 7:30 AM EDT - 2 years ago

Cyclerion Therapeutics Enters into Exclusive Negotiation Period and Binding Equity Investment Agreement

Mar 27, 2023, 7:00 AM EDT - 2 years ago

Cyclerion Therapeutics Receives U.S. FDA Orphan Drug Designation for Zagociguat for the Treatment of Mitochondrial Diseases

Mar 22, 2023, 4:40 PM EDT - 2 years ago

Cyclerion Reports Corporate Update and Full Year 2022 Financial Results

Nov 22, 2022, 7:00 AM EST - 3 years ago

Cyclerion Concludes Unsolicited Proposal Is Not in The Best Interest of The Company

Oct 6, 2022, 8:00 AM EDT - 3 years ago

Cyclerion Announces Mitochondrial Disease-Focused Corporate Strategy

Aug 9, 2022, 4:00 PM EDT - 3 years ago

Cyclerion Announces CY6463 Clinical Pipeline Progress and Second Quarter 2022 Financial Results

Jul 28, 2022, 7:00 AM EDT - 3 years ago

Cyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in Patients with Cognitive Impairment Associated with Schizophrenia (CIAS)

Jul 26, 2022, 7:00 AM EDT - 3 years ago

Steven E. Hyman, M.D., Appointed to Cyclerion Therapeutics' Board of Directors

Jun 28, 2022, 9:00 AM EDT - 3 years ago

Cyclerion Therapeutics Provides Additional Positive CY6463 MELAS Clinical Data at a Webinar Hosted by United Mitochondrial Disease Foundation

Jun 22, 2022, 8:30 AM EDT - 3 years ago

Cyclerion Therapeutics to Discuss CY6463 MELAS Clinical Data at a Webinar Hosted by United Mitochondrial Disease Foundation

Jun 17, 2022, 11:27 AM EDT - 3 years ago

Cyclerion Neurology Candidate Shows Encouraging Action In Preclinical Studies

Jun 17, 2022, 8:00 AM EDT - 3 years ago

Cyclerion Therapeutics Announces CY6463 Data Demonstrating Improved Cellular Energetics in Preclinical Models of Mitochondrial Disease

Jun 10, 2022, 7:00 AM EDT - 3 years ago

Cyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in MELAS Patients at UMDF Mitochondrial Medicine 2022 Symposium

Jun 6, 2022, 7:00 AM EDT - 3 years ago

Cyclerion Therapeutics to Share CY6463 MELAS Topline Study Results, CHOP to Present CY6463 Preclinical Data at UMDF Mitochondrial Medicine 2022 Symposium

May 4, 2022, 4:01 PM EDT - 3 years ago

Cyclerion Announces CY6463 Clinical Pipeline Progress and First Quarter 2022 Financial Results

Feb 24, 2022, 4:01 PM EST - 4 years ago

Cyclerion Announces CY6463 Clinical Pipeline and Corporate Updates

Feb 23, 2022, 8:00 AM EST - 4 years ago

Cyclerion Therapeutics and Ariana Pharma Announce an Artificial Intelligence-driven Precision Medicine Collaboration

Jan 26, 2022, 8:00 AM EST - 4 years ago

Cyclerion Therapeutics Announces Initiation of Patient Dosing in CY6463 Phase 2a Study in Alzheimer's Disease with Vascular Pathology

Nov 11, 2021, 5:32 PM EST - 4 years ago

Cyclerion Therapeutics to Participate in Jefferies London Healthcare Conference

Nov 9, 2021, 4:01 PM EST - 4 years ago

Cyclerion Therapeutics Reports Third Quarter 2021 Financial Results and Corporate Update

Oct 26, 2021, 4:29 PM EDT - 4 years ago

Cyclerion Therapeutics: Distressed Spinoff Developing New Medicines For CNS Disorders

Oct 20, 2021, 4:24 PM EDT - 4 years ago

Truist Bullish On This Clinical-Stage Biopharmaceutical Company With 374% Upside

Sep 22, 2021, 8:00 AM EDT - 4 years ago

Cyclerion Announces Publication of Preclinical Data Demonstrating Reduction in Neuroinflammation by Brain-Penetrant sGC Stimulator

Aug 23, 2021, 5:00 PM EDT - 4 years ago

Cyclerion Therapeutics to Present at Annual Biomarkers for Alzheimer's Disease Summit

Jul 29, 2021, 5:00 PM EDT - 4 years ago

Cyclerion Therapeutics Reports Second Quarter 2021 Financial Results and Corporate Update

Jul 22, 2021, 4:30 PM EDT - 4 years ago

Cyclerion Therapeutics to Present Clinical Trial Design for CY6463 Phase 2a Study in Participants with Alzheimer's Disease with Vascular Pathology at the Alzheimer's Association International Conference 2021 (AAIC)

Jul 9, 2021, 6:14 AM EDT - 4 years ago

Cyclerion Recruits Beacon Biosignals To Identify Disease-Relevant EEG Neurological Biomarkers

Jul 8, 2021, 7:22 PM EDT - 4 years ago

Beacon Biosignals and Cyclerion Therapeutics Announce Strategic Partnership

Jul 8, 2021, 4:30 PM EDT - 4 years ago

Cyclerion Therapeutics and Beacon Biosignals Announce Expanded Strategic Partnership

Jun 4, 2021, 10:27 AM EDT - 4 years ago

Cyclerion Out-Licenses Praliciguat to Akebia, Announces $18M Capital Raise

AKBA

Jun 4, 2021, 8:00 AM EDT - 4 years ago

Cyclerion Therapeutics Announces Global Licensing Agreement with Akebia Therapeutics for Praliciguat

Jun 4, 2021, 8:00 AM EDT - 4 years ago

Cyclerion Therapeutics Announces $18 Million Private Placement

May 27, 2021, 4:30 PM EDT - 4 years ago

Cyclerion Therapeutics Announces Publication of CY6463 Preclinical Data in Frontiers in Pharmacology

May 25, 2021, 7:00 AM EDT - 4 years ago

Cyclerion Therapeutics to Participate in Jefferies Virtual Healthcare Conference

Apr 27, 2021, 12:03 PM EDT - 5 years ago

Why Cyclerion, Sol-Gel, Aldeyra, DermTech and Bionano Genomics Are Moving Today

BNGO ALDX SLGL

Apr 27, 2021, 9:00 AM EDT - 5 years ago

Cyclerion Therapeutics Hosted Webinar to Discuss Pipeline Progress

Apr 26, 2021, 7:00 AM EDT - 5 years ago

Cyclerion Therapeutics Appoints Errol De Souza, Ph.D., to Board of Directors

Apr 21, 2021, 7:30 AM EDT - 5 years ago

Cyclerion Therapeutics to Participate in the B. Riley Neuroscience Investor Conference

Apr 20, 2021, 7:00 AM EDT - 5 years ago

Cyclerion Therapeutics to Host Pipeline Update Webinar

skyrockets_Inc Dec. 5 at 3:01 PM

1 · Reply

Mahdinur Dec. 4 at 6:43 PM

$CYCN $SMX $AGH $SMX $AGH $GRI

1 · Reply

Eliza1 Dec. 4 at 6:43 PM

$CYCN buy $SMX or $AGH- a better chance for gains. Be careful with $SMX. $AGH has lots of gaps over $7.5

0 · Reply

StockTwitsGhost Dec. 4 at 5:23 PM

$CYCN Thank you for selling, now we can retrace $9+

2 · Reply

skyrockets_Inc Dec. 4 at 5:07 PM

$CYCN the retrace to the 50day SMA is happening as predicted. Will re-trace back to ~$2 range soon IMO.

0 · Reply

AshleySchaeffer_BMW Dec. 4 at 4:38 PM

$CYCN vol perking up....

0 · Reply

dbr_island Dec. 4 at 4:34 PM

🚨EPOW🚨 loading here and can’t wait to show you my buys later once it runs BIG…… Just like QCLS 👇💰💰💰💰 $CYCN watching

0 · Reply

Eliza1 Dec. 3 at 11:35 PM

$CYCN time to sell

1 · Reply

Eliza1 Dec. 3 at 10:04 PM

$CAPR incredible move. This company has been around years with many RS but, still hangs in there. $$CYCN And $AGH could be next-

0 · Reply

Eliza1 Dec. 3 at 3:00 PM

$CYCN look at $CAPR for what a positive PR can do when you actually have good news! An 8k is required but not enough.

1 · Reply

Bullbear1010101 Dec. 3 at 12:48 AM

$CYCN manipulation 1.45! yesterday 1.64 aft hours

1 · Reply

WhaleSharksHF Dec. 2 at 8:27 PM

$SBFM hey babes! $3 incoming when they reveal those Bitcoin dip buys! 📝 The Stats Sunshine Biopharma: generics cash cow ($45M+ ’25 rev guided). Trading at 0.15x sales while peers sit 4–8x. Forgotten, low-float, now waking up. Snapshot (Dec 1, ’25) • Price: $1.45 • MCap: $6.6M • Float: ~3.5M • Short Interest: 13% of float • CTB: 26% 💡Smart Money Two Sigma filed new 21.4k share stake (Nov 14). Fund Sentiment Score 86.1/100 — top 7% most-accumulated stocks. Quants are in. ⚡️Catalysts • Q4 earnings Jan ’26 → profitability inflection + NIOPEG biosimilar launch • K1.1 mRNA liver cancer IND H1 ’25 • SBFM-PL4 antivirals Phase 1 Q2 ’25 • 12+ new generics H2 ’25 • $10M cash + BTC treasury, zero debt 💵 Valuation $50M ’26 rev, 15% margins → ~$25M EV base case. Fair value $5.50/share. Near-term PT $3.00 (+107% from $1.45). Analyst Aegis BUY $7, consensus $7.14 (390% upside). Load the dip. DYOR. Not financial advice. Verify facts. 🚀 $CYPH $CYCN $CYCU $GPUS

0 · Reply

WhaleSharksHF Dec. 2 at 7:17 PM

1 · Reply

NEWBIGTECH Dec. 2 at 5:58 PM

$CYCN $CYCU

2 · Reply

StockTwitsGhost Dec. 2 at 4:57 PM

$CYCN Maybe Mr. Aronson, Esq could write a press release highlight the positive developments with $AKBA since Cyclerion now apparently has him handling investor relations.

1 · Reply

StockTwitsGhost Dec. 2 at 4:51 PM

$CYCN got a $1M and possibility of tens of millions in regulatory milestones and the stock declines. Really Regina? A press release would have been ideal. Even I could write a PR from the slopes of Ski Butternut. JFC

1 · Reply

Mkt_predictor Dec. 2 at 3:47 PM

$CYCN on watch here for entry

0 · Reply

StockTwitsGhost Dec. 2 at 2:24 PM

$CYCN $CYCU got a million and mooned 📈 CYCN just got a million and the deal is worth up to $560M Someone wake them up in Cambridge. How bout some TRD phase 2 trial news and a $25M mixed shelf led by Gugg and JWood

1 · Reply

WhaleSharksHF Dec. 2 at 2:13 PM

$SBFM Bull Thesis – Nano-Cap Biotech Rocket 📝 The Stats Sunshine Biopharma: generics cash cow ($45M+ ’25 rev guided) funding oncology/antiviral pipeline. Trading at 0.15x sales (peers 4–8x). Low-float gem waking up. Snapshot (Dec 1, ’25) • Price: $1.45 • MCap: $6.6M • Float: ~3.5M • Short Interest: 13% • CTB: 26% 💡Smart Money Two Sigma new 21.4k stake (Nov 14). Fund Sentiment 86.1/100 — top 7% accumulated. Quants loading. ⚡️Catalysts • Q4 earnings Jan ’26: profitability + NIOPEG launch • K1.1 mRNA IND H1 ’25 • SBFM-PL4 Phase 1 Q2 ’25 • 12+ generics H2 ’25 • $10M cash/BTC, zero debt 💵 Valuation $50M ’26 rev, 15% margins → $25M EV base. Fair value $5.50/share. Near-term PT $3.00 (+107%). Analyst: Aegis BUY $7, consensus $7.14 (390% upside). 13% SI on 3.5M float + institutional buys = low-float squeeze setup. Load the dip—$3 soon? DYOR. Not advice. Verify. 🚀 $VSEE $CYCN $AMZE $CYCU

0 · Reply

StockTwitsGhost Dec. 2 at 1:46 PM

$CYCN Regina the material news you released in yesterdays 8-K is IMO absolutely PR worthy. Why is Cyclerion risk averse to properly promote positive information? Why not combine this with a corporate status update and stack the news. B school 101 how to properly promote the company.

1 · Reply

rjgra Dec. 2 at 4:58 AM

$CYCN https://archive.fast-edgar.com/20251201/AJ2ZG22FZ22RU2ZA222D22YPBUKDZZ22Z872/

0 · Reply

Eliza1 Dec. 2 at 1:14 AM

$CYCN a very positive PR for CYCN and it will show up in the price this week.

1 · Reply

Market Cap	6.01M
Revenue (ttm)	2.00M
Net Income (ttm)	-3.06M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-153.00%
Debt to Equity Ratio	0.00

Volume	14,075
Avg Vol	474,558
Day's Range	N/A - N/A
Shares Out	3.93M
Stochastic %K	91%
Beta	0.95
Analysts	Strong Buy
Price Target	$4.00